Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

×

This website is intended for US Healthcare Professionals

OPKO Connect provides comprehensive support

Patient assistance programs

For patients identified as not having affordable access to Rayaldee therapy, OPKO offers a free drug patient assistance program; eligibility criteria apply and annual re-enrollment is required.

Copay assistance

With this program, eligible commercially insured patients can fill their Rayaldee prescription for no more than $5 per month until the annual maximum limit is reached.

Starter dose program

This program provides a one-time-only free, 14-day supply of product to eligible patients whose initial Rayaldee coverage determination is delayed more than 5 days based on payer review timelines.

Prior authorization support

Can assist with any insurer-required PAs for Rayaldee on behalf of patients.

For information on how to request
exception coverage for Medicare Part D beneficiaries please visit www.cms.gov.

OPKO Connect services are available
by phone at 844‑414‑6756
Monday through Friday, 8 AM‑8 PM ET

Click here to download a Letter of Medical Necessity for Rayaldee Click here to download the Rayaldee Service Request form
Important Safety InformationBack to top
  • Hypercalcemia: Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium.
  • Digitalis toxicity: Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee.
  • Adynamic Bone Disease: Monitor for abnormally low levels of intact parathyroid hormone (iPTH) levels when using Rayaldee, and adjust dose if needed.
  • The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
  • Care should be taken while dosing Rayaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions.
  • Serum calcium should be below 9.8 mg/dL before initiating treatment.
  • Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and iPTH 3 months after starting therapy or changing dose.

Please see Full Prescribing Information.

OPKO recommends the use of its products only in accordance with the Food and Drug Administration (FDA)–approved prescribing information. Please refer to the full prescribing information for approved product labeling and important safety information.

Please report suspected side effects of Rayaldee to OPKO Pharmaceuticals, LLC. at 305-575-4226.

For more information about Rayaldee, please contact OPKO Medical Information at 1-844-729-2539 or medicalinformation@opko.com.

Important Safety Information

Hypercalcemia: Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium. • Digitalis toxicity: Potentiated by hypercalcemia of any cause.

Abbreviations

1,25D = 1,25-dihydroxyvitamin D
25D = 25-hydroxyvitamin D
CKD = chronic kidney disease
CV = cardiovascular
iPTH = intact parathyroid hormone
SHPT = secondary hyperparathyroidism

References
  1. Rayaldee [prescribing information]. Miami, FL: OPKO Pharmaceuticals, LLC; June 2016.
  2. Sprague SM, Crawford PW, Melnick JZ, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016;44:316–325.
  3. Data on file. OPKO Pharmaceuticals, LLC;2016.
  4. Schumock GT, Andress DL, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron Clin Pract. 2009;113(1):54–61.
  5. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38.
  6. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–921.
  7. Cozzolino M, Covic A, Martinez-Placencia B, Xynos K. Treatment failure of active vitamin D therapy in chronic kidney disease: Predictive factors. Am J Nephrol. 2015;42:228–236.
  8. International Society of Nephrology. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD). Kidney Int. 2009;76(113):S50-S99.
  9. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005;45:1026–1033.
  10. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75:88–95.
  11. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20:1453–1464.

RAYALDEE is a registered trademark of OPKO Ireland Global Holdings Ltd.
OPKO Renal is a division of OPKO Health, Inc.
© 2017 OPKO Pharmaceuticals, LLC. All rights reserved.
Contact Us / Privacy Policy / Terms of Use
OP-US-0214-102017v.1